cyrilzakka/clinical-trials huggingface dataset:
Exercise Incentives for YMCA Based Exercise

The investigators will conduct a randomized controlled trial to test financial incentive programs (versus control) to promote physical activity among 330 adults who have a YMCA membership. Participants will have the opportunity to earn up to $100 or $200 (depending on the condition they are assigned to) for attending at least 50 sessions at the YMCA over 6 months. Participants will have two 6-month windows during which they will have the opportunity to earn the incentive. In addition to the incentives, participants will complete research assessments every 3 months.


Eligibility Criteria:
Inclusion Criteria:

1. A current member, or willing to become a current member of one of the following branches of the YMCA:

   1. Bayside Family YMCA (Barrington, RI)
   2. Cranston YMCA (Cranston, RI)
   3. East Side/Mt. Hope YMCA (Providence, RI)
   4. Kent County YMCA (Warwick, RI)
   5. Newman YMCA (Seekonk, MA)
   6. South County YMCA (South Kingston, RI)
2. Age 18 years or older
3. Physically capable of engaging in exercise

Exclusion Criteria:

1. Not a current member, and unwilling to become a member of one of the above listed YMCA branches.
2. Under age 18.
3. Physically incapable of exercise
4. Doctor has recommended that you should not exercise because of a current health condition
Prevalence of Sonographic Abnormalities of Joints and Entheses in Psoriasis Patients With or Without Musculoskeletal Complains

The objectives of this study are:

* to estimate the prevalence and severity of inflammatory (synovitis, tenosynovitis, enthesitis, dactylitis) and structural (erosions, osteophytes, enthesophytes, cortical irregularities ) ultrasound lesions in psoriasis patients with or without related musculoskeletal symptoms;
* to compare them to healthy subjects or patients suffering from rheumatoid arthritis and osteoarthritis.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years;
* Psoriasis diagnosed by a dermatologist;
* Able to participate in the study;
* Informed consent signed.

Exclusion Criteria:

- Chronic disease likely to cause musculoskeletal symptoms (connective tissue diseases, inflammatory bowel diseases, overload disorders, crystal related arthritis, septic arthritis...).
Endoscopic Surgery or Radiation Therapy in Treating Patients With Stage 0, Stage I, or Stage II Laryngeal Cancer of the Glottis

RATIONALE: Endoscopic surgery is a less invasive type of surgery for laryngeal cancer and may have fewer side effects and improve recovery. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether endoscopic surgery is more effective than radiation therapy in treating laryngeal cancer of the glottis.

PURPOSE: This randomized phase II trial is studying endoscopic surgery to see how well it works compared with radiation therapy in treating patients with stage 0, stage I, or stage II laryngeal cancer of the glottis.

OBJECTIVES:

* Determine the feasibility of conducting a large phase III randomized study in the future, comparing radiotherapy vs endoscopic excision in patients with stage 0-II laryngeal cancer of the glottis.
* Determine patient acceptability of the proposed trial design.
* Compare the effect of using dedicated head and neck research nurses vs general nurses on patient recruitment.
* Refine outcome measures, including voice analysis and quality of life.

OUTLINE: This is a randomized, controlled, multicenter, pilot study. Patients are stratified according to participating center and T stage (Tis or T1 vs T2a). Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients undergo endoscopic excision via CO_2 laser or cold steel.
* Arm II: Patients undergo radiotherapy once daily, 5 days a week, for 3-4 weeks. Patients undergo vocal analysis at baseline and at 6 months and 1 and 2 years after randomization.

Quality of life is assessed at baseline, at 1 year, and then annually for 5 years.

After completion of study treatment, patients are followed periodically for up to 5 years.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Histologically confirmed squamous cell carcinoma of the glottic larynx, including tumors at the anterior commissure

  * Stage 0-II (Tis, T1, or T2a)
* No clinical or radiological sign of nodal involvement
* No evidence of distant metastases
* Airway anatomy suitable for endoscopic excision

PATIENT CHARACTERISTICS:

* Fit to receive radical treatment as either radiotherapy or endoscopic excision
* Life expectancy ≥ 2 years
* No other cancer in the past 10 years except basal cell carcinoma of the skin or adequately treated carcinoma in situ of the uterine cervix
* No vasculitic conditions adversely affecting radiotherapy
* No other co-existing medical condition that would limit life expectancy
* Not pregnant

PRIOR CONCURRENT THERAPY:

* No concurrent chemotherapy
* No concurrent palliative treatment
Severe COVID-19 Infection in Children Presenting to EDs in Israel and England

Even though the COVID-19 pandemic is no longer at its peak, the threat still lingers. Engaging in prospective surveillance studies will enable us to monitor the disease and prepare for any potential resurgence. COVID-19 surveillance studies are essential tools for policymakers to make informed decisions, allocate resources, and develop strategies to control the spread of the virus and protect public health.

The objective of this surveillance study is to prospectively assess in-hospital severe morbidity related to COVID-19 infection in children who present to the Pediatric Emergency Department (ED).

A prospective multicenter study will be conducted across eight EDs in Israel and five EDs in the United Kingdom. The study population will include children aged 16 years or younger with a severe acute COVID-19 infection. Confirmation of acute COVID-19 infection will be based on polymerase chain reaction nasopharyngeal swab testing. The study will also include patients diagnosed with multisystem inflammatory syndrome in children (MIS-C), as defined by the CDC.


Eligibility Criteria:
Inclusion Criteria:

1. SACI

   Patients aged 16 years or younger with a positive COVID-19 PCR nasopharyngeal swab testing or bronchoalveolar sample who meet the definition of SACI:
   * Receive oxygen via low-flow nasal cannula or oxygen mask, high-flow nasal cannula, bilevel or continuous positive airway pressure machine, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) Or
   * Admitted to ICU
2. MIS-C Patients aged 16 years or younger diagnosed with MIS-C
Influenza Vaccine Elicited Immune Response in Immunocompromised Patients

This study aims to understand how well influenza vaccines work in some individuals with weakened immune systems compared to healthy individuals. Some people, such as those with HIV, multiple sclerosis, certain cancers, or autoimmune conditions, have more severe influenza disease courses due to their medical treatments. These individuals may also respond less effectively to vaccines. By comparing immune responses to the influenza vaccine in both immunocompromised patients and healthy participants, this study aims to identify patterns in vaccine effectiveness and side effects. The goal is to find better ways to predict vaccine response in vulnerable patients and improve protection against influenza.

The study is a single-center, prospective cohort study evaluating influenza vaccine responses in adults with weakened immune systems compared to healthy adults. Immunocompromised participants include individuals with HIV, multiple sclerosis, rheumatological diseases, and B-cell malignancies after CAR-T cell therapy. All participants will receive a standard influenza vaccine, as recommended in Switzerland, with immune response measured through blood tests at specific time points before and after vaccination.

The primary objective is to compare influenza vaccine antibody levels in immunocompromised and healthy participants to determine if immune responses are different in the former group. Secondary objectives include examining vaccine-induced immune cell activity, side effects, and the immune profile before vaccination in each patient subgroup. The study will also analyze gut microbiome differences between responders and non-responders and develop prediction models for vaccine effectiveness based on immune and demographic data. By doing so, researchers hope to enhance the understanding of how best to protect immunocompromised patients against influenza.

Eligibility Criteria:
Inclusion Criteria:

* ≥ 18 years old
* Diagnosed with rheumatological diseases on immunosuppressive therapies, or Multiple sclerosis on immune modulating therapies, or B-cell malignancies after CAR-T cell therapy, or o PLWH with CD4 cell count \>200/ul, or Non-immunocompromised individuals attending the University Clinic for Infectious Diseases to receive influenza vaccination.
* Provided written informed consent.

Exclusion Criteria:

* For People Living With HIV: untreated or ≥2 measured viral loads above 50cp/ml in preceding 6 months
* For non-immunocompromised controls: any inborn or acquired condition resulting in immunosuppression.
* Receiving B-cell depleting therapies in last 12 Months for MS, RA patients and PLWH
* Receipt of Immunoglobulin-therapy (IVIG) ≤4 months prior to the drawing of study samples
* \< 18 years old
* Lack of written informed consent
Moving Forward Together 4

This is a 3-month physical activity intervention aimed to increase moderate-intensity activity among previously inactive breast cancer survivors. Participants will be eligible if they are not currently active, and have recently been diagnosed with breast cancer. Upon eligibility, participants will be randomized into one of two groups. The intervention group will receive weekly guidance from a peer coach to increase their activity throughout the three month intervention. The control group will be encouraged to self-monitor their physical activity throughout the three month intervention. Both groups will receive a Fitbit. Peer coaches will be trained to deliver the physical activity program using a web-based platform; all calls will be virtual. Participants will be assessed before and after the intervention.


Eligibility Criteria:
Participants:

Inclusion Criteria:

* Diagnosed in the past 5 years with Stage 0-3 breast cancer
* Able to read and speak English
* Ambulatory
* Sedentary (\<30 minutes of vigorous-intensity physical activity, \<90 min of moderate-intensity physical activity in the past 6 months)
* Able to walk unassisted
* Access to a smartphone with Bluetooth and internet

Exclusion Criteria:

* Stage 4 cancer
* Medical or psychiatric problem that may interfere with protocol adherence

Peer Mentor Coaches:

Inclusion criteria:

* Current peer coach (at least one year)
* Have a valid email address, telephone access, and access to a tablet/computer
* Willing to participate in group training
* Willing to be supervised using platform
* Currently exercise for at least 60 min/week of moderate-intensity activity
Study to Assess the Impact of Personalized Coaching on the Time Period and Quality of Return to Work After Breast Cancer

Evaluate the impact of coaching sessions on the return to work rate (number of patients returning at work / total number of patients per arm) 6 months after inclusion in the study for breast cancer in professionnally active patients.


Eligibility Criteria:
Inclusion Criteria:

Any patient active at the time of the diagnosis of breast cancer, treated consecutively at the Institut Curie during the study period, and whose first treatment will be surgery, will be offered participation in the study.

1. Invasive non-metastatic breast cancer, treated first by surgery
2. Age ≥ 18 and ≤ 60 years
3. Active woman at the time of diagnosis
4. Patient with internet access and email address
5. Patient affiliated with a social security scheme, speaking and reading French
6. Signature of informed consent

Exclusion Criteria:

1. In situ breast cancer
2. History of breast cancer
3. Metastatic breast cancer
4. Inflammatory Breast Cancer
5. Woman with a life expectancy \<6 months at the time of diagnosis (in relation to other serious chronic diseases)
6. Persons deprived of liberty or under guardianship
7. Impossibility to submit to the medical follow-up of the test for geographical, social or psychological reasons
Feasibility of a Self-performed Urinary Test for the Follow-up on Medical Abortion

This study was a national, longitudinal, prospective, observational survey, carried out in metropolitan France, with a sampling of 21 birth control centres.

The aim of this study was to assess, in real life conditions, the benefit of a urinary semi-quantitative test (hCG Duo 5-1000) in the follow-up of medical abortion by analysing the concordance between qualitative results from the urinary test and quantitative values from the beta-hCG blood measurement.


Eligibility Criteria:
Inclusion Criteria:

* Adult women (18 years old or more), pregnant the day of the medical examination and asking for medical abortion.
* Patients agreeing to participate in the study after have been informed orally by the physician and given the information sheet.
* Informed patients accepting the computer processing of their medical data and their right of access and correction.

Exclusion Criteria:

* Patients with more than 49 Days of Amenorrhea (DA) for private practice and 63 DA for hospital practice.
* Patients with contraindications to medical abortion.
* Patients with severe and progressive disease.
* Patients unable to complete a questionnaire.
* Patients refusing to participate in the study.
Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients

The primary objective of this study is to determine the feasibility of four weeks of preoperative immunotherapy with Nivolumab, and Nivolumab plus Relatlimab in patients with early stage or locally advanced non-small cell lung cancer eligible for curative resection.


Eligibility Criteria:
Inclusion Criteria:

* Patients with histologically confirmed non-small cell lung cancer (NSCLC) eligible for anatomic resection (Clinical stages I B, II and selected stage III A)
* Eastern Cooperative Oncology Group (ECOG) ≤ 1
* Sufficient pulmonary function to undergo curative lung cancer surgery
* Adequate hematological, hepatic and renal function parameters:
* Sufficient cardiac left ventricular defined as left ventricular ejection fraction (LVEF) ≥ 50% documented either by echocardiography or multigated acquisition scan (MUGA)
* Patient able and willing to provide written informed consent and to comply with the study protocol and with the planned surgical procedures

Exclusion Criteria:

* Active or history of autoimmune disease or immune deficiency
* Subjects with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration
* Subjects who have undergone organ transplant or allogeneic stem cell transplantation
* Uncontrolled or significant cardiovascular disease
* Patients with active neurological disease
* Active malignancy or a prior malignancy within the past 3 years
* Receipt of live attenuated vaccine within 30 days prior to the first dose of study medication
* Peripheral polyneuropathy NCI CTCAE Grade ≥ 2
* History of gastric perforation or fistulae in past 6 months
* Serious or non-healing wound, ulcer, or bone fracture within 28 days prior to enrollment.
* The patient has undergone major surgery within 28 days prior to enrollment except staging mediastinoscopy, diagnostic Video Assisted Thoracoscopic Surgery (VATS) or implantation of a venous port-system.
* Any other concurrent preoperative antineoplastic treatment including irradiation
* Pregnant/Breastfeeding women
* Subjects with history of severe toxicity or life-threatening toxicity (grade 3 or 4) related to prior immune therapy
* Prior treatment with Lymphocyte-activation gene 3 (LAG-3) targeting Agent
* Previous treatment with Nivolumab or Relatlimab
Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants

The study will have 2 independent parts:

Part 1 of the study is intended to collect samples for Metabolites in Safety Testing (MIST) analysis after administration of multiple doses of zibotentan.

Part 2 of the study is designed to evaluate the relative bioavailability of zibotentan and dapagliflozin after dosing with two different fixed-dose combination (FDC) formulations and dosing with separate formulations of zibotentan and dapagliflozin.

Part 1 will be an open-label, non-randomised, single treatment period. A single treatment period during which participants will be resident at the study centre from 2 days before dosing (Day -2) until the morning of Day 6.

Part 2 will be an open-label, randomised, 3-period, 3-treatment, cross-over single dose study. Participants will be randomised to one of 3 treatment sequences and will receive 3 single-dose study interventions. Participants will be resident at the study centre from 2 days before dosing (Day -2) until Day 3 of the last treatment sequence.

Participants who were enrolled in Part 1 may not be enrolled in Part 2.

Eligibility Criteria:
Inclusion Criteria:

For inclusion in the study participants should fulfil the following criteria:

1. Participants with suitable veins for cannulation or repeated venipuncture.
2. Females must have a negative pregnancy test at the Screening Visit and within 24 hours prior to dosing, must not be lactating and must be of non- childbearing potential
3. Male participant must adhere to the contraception methods.
4. Have a BMI between 18 and 29.9 kg/m\^2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.
5. Provision of signed and dated, written informed consent prior to any study specific procedures.

Exclusion Criteria:

Participants will not enter the study if any of the following exclusion criteria are fulfilled:

1. History or presence of gastrointestinal, hepatic or renal disease or any important disease or disorder.
2. Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of study intervention.
3. Any clinically significant abnormalities in clinical chemistry, haematology, or urinalysis.
4. Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody, and Human immunodeficiency virus antibody.
5. Abnormal vital signs. 6 History of drug abuse or alcohol abuse.

7. History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity.

8. Participants who are vegans or have medical dietary restrictions. 9. Participants tested positive for COVID-19 at the time of randomisation or have been previously hospitalised with COVID-19 infection.
ABO-Incompatible Kidney Transplants Between Robot-Assisted vs. Open Surgery

While robot-assisted kidney transplantation (RAKT) offers potential benefits such as minimal postoperative pain, better cosmesis, fewer wound infections, and shorter hospital stay, its efficacy in ABO-incompatible (ABO-i) KT compared to open KT (OKT) remains understudied. This study aims to compare ABO-i KT outcomes between RAKT and OKT.

The study utilized data from 29 ABO-i RAKT and 210 ABO-i OKT cases performed at Asan Medical Center from October 2020 to February 2023. Univariate and multivariate analyses were performed to evaluate factors associated with a composite of biopsy-proven acute rejection (BPAR), de novo donor-specific antibodies (DSA), and overall graft failure.


Eligibility Criteria:
Inclusion Criteria:

* Patient eligible for living donor ABO incompatible kidney transplantation
* Presenting an IsoAgglutinin immunoglobulin G titer (anti-A-B) between 1/8 and 1/128 before operation
* Patient older than 18 years and young than 80 years
* Patient able to sign an informed consent form

Exclusion Criteria:

* Patient with comorbidities or hypersensitivity that prevent desensitization protocols
* Women who are pregnant, or who may become pregnant or breastfeeding women
* Subjects under legal protection
* Subjects participating in another interventional research protocol or in an exclusion period from another interventional research protocolPatient affiliated with a social security scheme
An fMRI Study Of Brain Response In Patients With Fibromyalgia

The purpose of this study is to explore how pregabalin works in patients with fibromyalgia by evaluating brain imaging signals. To find out whether fMRI (functional magnetic resonance imaging) is an efficient way to show whether new pain medications are effective in treating fibromyalgia.

Methodology study

Eligibility Criteria:
Inclusion Criteria:

* Women must have pain due to fibromyalgia
* Fibromyalgia must have been diagnosed at least 6 months prior to be eligible for this study

Exclusion Criteria:

* Patients with severe depression or other serious illness, who are left-handed, or who are pregnant or nursing are not eligible for this study.
The Role of Bathing Additives in the Treatment of Pediatric Atopic Dermatitis

To evaluate the efficacy of water bath, water + bleach, and water + vinegar (acetic acid) in the treatment of atopic dermatitis (eczema)

To perform a randomized controlled study to evaluate the efficacy of adding dilute acetic acid to the bath twice weekly on the Eczema Area and Severity Index (EASI) score as compared to adding dilute bleach to the bath including a control arm in which no solution is added to the bath.

Eligibility Criteria:
Inclusion Criteria:

* Currently reside in the USA
* Ability to comply with follow up visits at 2-4 months and at 6 months
* Come to the last follow-up at 6 months in the clinic
* At least 5% Body Surface Area (BSA) affected with AD

Exclusion Criteria:

* Unclear diagnosis of atopic dermatitis
* Inability to comply with additive baths
* Inability to comply with follow-up visits
* Lack of residence in the United States
A Study of Compliant Behaviors and Associated Factors of Women Breast Screening

There were a breast cancer screening activity in Taipei Medical University-Shuang Ho Hospital. We did an intervention with woman who joined the activity.The most important part in the intervention was to know health behavior about the breast cancer prevention.By doing the study, the investigators will know how to promote the health activity in our community.

When the investigators get these women's health behavior imagination, the investigators can know how much breast cancer screening activity do these people have. The most important part for us is to understand how to promote health behavior to women who live around Shuang area.

Eligibility Criteria:
Inclusion Criteria:

1. women
2. can read words

Exclusion Criteria:

NA